TM-38837 is a small molecule inverse agonist/antagonist of the CB1 cannabinoid receptor, with peripheral selectivity.

It is being developed for the treatment of obesity and metabolic disorders by 7TM Pharma.

[1] The company has announced phase I clinical trials.

TM-38837 is among the first of a new generation of cannabinoid receptor antagonist designed to avoid the central nervous system liabilities of the first generation CB1 receptor antagonists such as rimonabant.

[2] This cannabinoid related article is a stub.